Research programme: CD26 antigen antagonists - Point Therapeutics

Drug Profile

Research programme: CD26 antigen antagonists - Point Therapeutics

Alternative Names: PT-630

Latest Information Update: 14 Feb 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tufts University
  • Developer Midatech Pharma US
  • Class Pyrrolidines; Small molecules
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Type 2 diabetes mellitus

Most Recent Events

  • 12 Feb 2008 Point Therapeutics has been acquired and merged into DARA Biosciences
  • 10 Nov 2006 Suspended - Preclinical for Type-2 diabetes mellitus in USA (unspecified route)
  • 09 Mar 2006 Preclinical data from a media release have been added to the Diabetes pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top